Lung Therapeutics, Inc. Chief Scientific Officer Dr. Steven Idell Receives NIH Grant for Phase 1A/1B Clinical Trial of Drug Candidate LTI-01

October 27, 2015

European Orphan Drug Designation gives Lung Therapeutics 10 years of market exclusivity in Europe for LTI-01 in the treatment of empyema, a complication of pneumonia. AUSTIN and TYLER, TX — October 27, 2015 —  Lung Therapeutics, Inc., a pharmaceutical company focused on niche, orphan drug indications addressing unmet therapeutic needs in lung injury and disease,...
Read more...

Lung Therapeutics, Inc. Granted Orphan Drug Designation in the European Union for LTI-01

January 13, 2015

European Orphan Drug Designation gives Lung Therapeutics 10 years of market exclusivity in Europe for LTI-01 in the treatment of empyema, a complication of pneumonia. AUSTIN, TX — January 13, 2015 —  Lung Therapeutics, Inc., a pharmaceutical company focused on niche, orphan drug indications addressing unmet therapeutic needs in lung injury and disease, announced that...
Read more...

Lung Therapeutics, Inc. Receives FDA Orphan Drug Designation for Lead Drug Candidate LTI-01

December 2, 2014

FDA Orphan Drug Designation gives Lung Therapeutics a seven-year US market exclusivity for LTI-01 in the treatment of empyema, typically a complication of pneumonia. LTI-01 is designed to reduce fibrinous scars in the lung cavity to allow fluid drainage without the need for surgery. AUSTIN, TX — December 2, 2014 —  Lung Therapeutics, Inc., a...
Read more...

Pharma start-up Lung Therapeutics, Inc. achieves significant funding to address unmet needs in lung injury and disease

October 28, 2014

Lung Therapeutics closes $1,550,000 of its initial Series A Preferred Stock financing, with additional milestone-driven commitments totaling $2,750,000. AUSTIN, TX — October 28, 2014 —  Lung Therapeutics, Inc., a pharmaceutical company focused on niche, orphan drug indications in lung injury and disease, has closed on $1,550,000 in the initial closing of its Series A Preferred...
Read more...

Company Address

1515 S. Capital of Texas Highway

Suite 402

Austin, Texas 78746

Phone: +1 512.872.7527

Email: info@lungtx.com

Media Contact

Sandra Oak

Nsight Public Relations

Phone: +1 321.591.1508

Email: soak@nsightpr.com